TY-JUR T1 - 泼尼松龙的随机试验与泼尼松龙和伊丙酮在急性阶段过敏性支气管肺肺血管诊断复杂性哮喘jf - 欧洲呼吸杂志jo - EUR RESPIR J DO - 10.1183 / 13993003.01787-2021 SP - 2101787Au - Agarwal，Ritesh Au - Muthu，Valliappan Au - Sehgal，Inderpaul Singh Au - Dhooria，Sahajal Au - Prasad，Kuruswamy Thurai Au - Garg，Mandep Au - Aggarwal，Ashutosh Nath Au - Chakrabarti，Arunaloke Y1 - 2021/01/01UR - //www.qdcxjkg.com/content/early/2021/09/02/13993003.01787-2021.abstract n2 - 糖皮质激素和抗真菌三唑的组合是优于糖皮质激素，在减少患者的情况下，过敏性支气管肺曲霉病（ABPA）仍然未知。我们旨在比较泼尼斯伊替甘甘唑组合与泼尼松龙单疗法在ABPA的疗效和安全性.WE随机受试者用治疗 - 天真急性阶段ABPA复杂化哮喘仅接受泼尼松龙（四个月）或泼尼松龙和伊唑啉代和伊霉唑的组合（四和六个月分别）。主要结果在12个月和糖皮质激素依赖性ABPA在启动治疗后24个月内得到加剧率。关键的二次结果是六周内血清总IgE的反应率和百分比下降，首先是第一次ABPA加剧，以及治疗紧急的不良反应（AE）.we随机化191受试者接受泼尼松（n = 94）或泼尼松 -伊丙酮组合（n = 97）。泼尼松龙的一年加油率为33％和20.6％，分别是泼尼松龙 - 伊丙酮武器（P = 0.054）。任何参与者都没有进入糖皮质激素依赖性ABPA。 All the subjects experienced a composite response at 6-weeks, along with a decline in serum total IgE (mean decline, 47.6% versus 45.5%). The mean time to first ABPA exacerbation (417 days) was not different between the groups. None of the participants required modification of therapy due to AE.There was a trend towards a decline in ABPA exacerbations at 1-year with the prednisolone-itraconazole combination than prednisolone monotherapy. A three-arm trial comparing itraconazole and prednisolone monotherapies with their combination, preferably in a multicentric design, is required to define the best treatment strategy for acute-stage ABPA.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: RA has received grant support for conducting research in ABPA from Cipla Pharmaceuticals, Mumbai, India, outside the submitted work.Conflict of interest: VM has nothing to disclose.Conflict of interest: ISS has nothing to disclose.Conflict of interest: SD has nothing to disclose.Conflict of interest: KTP has nothing to disclose.Conflict of interest: MG has nothing to disclose.Conflict of interest: ANA has nothing to disclose.Conflict of interest: AC has nothing to disclose. ER -